TNF-α and IL-8 in Acute Stroke and the Modulation of these Cytokines by Antiplatelet Agents

Stroke is associated with elevation of several proinflammatory cytokines such as tumor necrosis factor alpha (TNF-α) and interleukin (IL)-8 that are correlated with central nervous system (CNS) injury. Anti-platelet therapies are important agents in stroke management. The role of antiplatelets as anti-inflammatory agents is not known in acute stroke patients. Furthermore, their effect on induction of potential cytokines as TNF-α and IL-8 in those patients is still not clear. Thus, we herein examined the induction of TNF-α and IL-8 in acute stroke patients and examined the effects of the antiplatelets drugs aspirin, clopidogrel and dipyridamole, and piracetam in their induction. Cytokines were detected intracellularly in leukocytes from patients who had first acute ischemic stroke and from matched controls by immunocytochemistry. The results showed significant increase of spontaneously produced TNF-α and IL-8 in patients compared to control. This induction was significantly inhibited differently by each drug and dual drug agents. The data of this work suggest that antiplatelets agents may have a role in inhibition of stroke mediated proinflammatory cytokine effects, which may initiate a new aspect of the role of antiplatelets in the treatment of acute ischemic stroke.

[1]  R. Tamargo,et al.  Inflammation in stroke and focal cerebral ischemia. , 2006, Surgical neurology.

[2]  T. Meinertz,et al.  Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease: Evidence for Antioxidant and Antiinflammatory Effects , 2006, Arteriosclerosis, thrombosis, and vascular biology.

[3]  M. Uchiba,et al.  Dalteparin, a low molecular weight heparin, attenuates inflammatory responses and reduces ischemia-reperfusion–induced liver injury in rats* , 2006, Critical care medicine.

[4]  C. Kim,et al.  Cilostazol Suppresses Superoxide Production and Expression of Adhesion Molecules in Human Endothelial Cells via Mediation of cAMP-Dependent Protein Kinase-Mediated Maxi-K Channel Activation , 2006, Journal of Pharmacology and Experimental Therapeutics.

[5]  Lidong Zhang,et al.  Pentoxifylline Decreases Up-Regulated Nuclear Factor kappa B Activation and Cytokine Production in the Rat Retina following Transient Ischemia , 2006, Ophthalmologica.

[6]  R. Kast.  Aspirin use in myeloma: a note of caution regarding potential tumour necrosis factor‐alpha elevation , 2006, British journal of haematology.

[7]  Y. Akasaka,et al.  Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction , 2006, Modern Pathology.

[8]  N. Rothwell,et al.  The role of inflammation in CNS injury and disease , 2006, British journal of pharmacology.

[9]  D. Dixon,et al.  Dipyridamole Selectively Inhibits Inflammatory Gene Expression in Platelet–Monocyte Aggregates , 2005, Circulation.

[10]  H. Kulbertus.  [Aspirin: recent advances in cardiovascular prevention]. , 2004, Revue medicale de Liege.

[11]  Chaur-Jong Hu,et al.  Aspirin inhibits monocyte chemoattractant protein-1 and interleukin-8 expression in TNF-alpha stimulated human umbilical vein endothelial cells. , 2004, Atherosclerosis.

[12]  Alex Rovira,et al.  Plasmatic Level of Neuroinflammatory Markers Predict the Extent of Diffusion-Weighted Image Lesions in Hyperacute Stroke , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[13]  E. Schryver.  Dipyridamole in Stroke Prevention: Effect of Dipyridamole on Blood Pressure , 2003 .

[14]  A. Algra,et al.  Cochrane Review: Dipyridamole for Preventing Major Vascular Events in Patients With Vascular Disease , 2003, Stroke.

[15]  M. Alberts,et al.  Clopidogrel plus aspirin for stroke prevention. , 2002, Stroke.

[16]  Hirofumi Nakatomi,et al.  Regeneration of Hippocampal Pyramidal Neurons after Ischemic Brain Injury by Recruitment of Endogenous Neural Progenitors , 2002, Cell.

[17]  C. Warlow.  Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke. , 2002, Stroke.

[18]  W. Lalouschek,et al.  Current Strategies of Secondary Prevention After a Cerebrovascular Event: The Vienna Stroke Registry , 2001, Stroke.

[19]  A. Grau,et al.  Increased cytokine release by leucocytes in survivors of stroke at young age , 2001, European journal of clinical investigation.

[20]  P. Bath,et al.  Effects of combining three different antiplatelet agents on platelets and leukocytes in whole blood in vitro , 2001, British journal of pharmacology.

[21]  R. D'Agostino,et al.  Therapeutic benefit. Aspirin revisited in light of the introduction of clopidogrel. , 1999, Stroke.

[22]  M. Bednar,et al.  Antiplatelet therapy in acute cerebral ischemia. , 1999, Stroke.

[23]  R. de Caterina,et al.  Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. , 2004, European heart journal.

[24]  G. Feuerstein,et al.  Cerebrovascular Disease: Inflammation and stroke: benefits or harm? , 2002 .

[25]  P A Wolf,et al.  Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. , 2001, Circulation.